Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAIN-2: Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer
NCT01996267Phase 3Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Dec 2013
- Primary completion
- Dec 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of pertuzumab in HER2-positive breast cancer, sponsored by Netherlands Cancer Institute. Started Dec 2013; status: active, not recruiting.
02
Drugs
pertuzumab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT01996267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01996267.